Professor Steve Kerrigan from RCSI School of Pharmacy and Biomolecular Sciences has been researching #sepsis for 25 years. In this piece for #WorldSepsisDay he speaks to RTÉ News about raising awareness of the illness and how it is caused. ⬇️ rte.ie/news/health/20…

Delighted to be shortlisted for the Innovation Award at the Future Health Summit 2025 2024. Inthelia is a cutting-edge biopharmaceutical company focused on transforming the landscape of precision medicine in infection. Steve Kerrigan RCSI RCSI School of Pharmacy and Biomolecular Sciences

🌟 Big announcement! 🌟 Introducing the new #IntheliaTherapeutics website – your gateway to groundbreaking innovations in the global fight against infection and #sepsis. Go to inthelia.com to explore! 💊💡 #IntheliaTherapeutics RCSI Research and Innovation

We are delighted to be named winners of the Innovation Award at the #Investnet #FutureHealthSummit2024 for our innovative approach in developing a drug to treat sepsis, a condition that poses significant challenges. RCSI RCSI Research and Innovation RCSI School of Pharmacy and Biomolecular Sciences Future Health Summit 2025

Thank you! We're honored to have our work recognized. UPMC sponsorship and support are invaluable in advancing innovative solutions like our precision approach to treat and diagnose serious infections. RCSI RCSI Research and Innovation